Weltruza (olanzapine)

Where it stands

Weltruza (olanzapine) is approved in the US. The records show an FDA approval dated 2026-10-08 for Teva under NDA219007. The record is marked official.

The records do not give a therapeutic area or an indication. They show no CHMP opinion date, which is expected for a US-only product. The only formulation detail is "powder". The route of administration, strength and intended patient population are not stated, so they should be confirmed from the approved labelling.

Regulatory pathway and designations

The FDA classified the approval as "New formulation or manufacturer". This is the only designation in the records. It indicates the approval concerns a new presentation or source of an already-known active substance, not a new molecular entity. Olanzapine is already authorised in the EU under several brands, including Zyprexa, Zypadhera, Olazax, Olazax Disperzi, Olanzapine Glenmark and Olanzapine Glenmark Europe. The records do not say whether the FDA has other olanzapine products on the market.

The records do not say which NDA sub-pathway was used, for example a full application or one that relies partly on existing data. They also do not list any expedited designations, orphan status, exclusivity or a PDUFA date. No inference should be drawn on these points from the records alone.

Safety and pharmacovigilance

The records contain no safety data. They have no labelled warnings, adverse event information, risk management requirements or post-marketing commitments for Weltruza.

Because the active substance is established and authorised elsewhere, a reader would normally compare the approved US label with the labelling of the reference products. The aim is to see whether the new formulation changes dosing, administration or risk-minimisation measures. The records do not allow that comparison.

What to watch

The first step is to obtain the approved FDA label and approval documents. These should confirm the indication, dosage form, route of administration and any formulation-specific warnings or post-marketing requirements.

It is also worth tracking whether Teva announces a US launch timeline or files for this formulation in other regions. The records show no such plans. The EU olanzapine products listed are separate authorisations and do not indicate that Weltruza will be approved there.